95 related articles for article (PubMed ID: 10631701)
1. Testicular cancer: what's new in staging, prognosis, and therapy.
Foster RS; Nichols CR
Oncology (Williston Park); 1999 Dec; 13(12):1689-94; discussion 1697-700, 1703. PubMed ID: 10631701
[TBL] [Abstract][Full Text] [Related]
2. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
4. [Effect of biological prognostic factors on therapy of non-seminomatous stage I testicular tumors--an assessment of the current status].
Kuczyk MA; Bokemeyer C; Serth J; Machtens S; Höfner K; Jonas U
Urologe A; 1996 Jan; 35(1):35-45. PubMed ID: 8851847
[TBL] [Abstract][Full Text] [Related]
5. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience.
Hyams ES; Pierorazio P; Proteek O; Sroka M; Kavoussi LR; Allaf ME
J Urol; 2012 Feb; 187(2):487-92. PubMed ID: 22177913
[TBL] [Abstract][Full Text] [Related]
6. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis.
Sogani PC
Urol Clin North Am; 1991 Aug; 18(3):561-73. PubMed ID: 1652171
[TBL] [Abstract][Full Text] [Related]
8. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Klein EA
BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
[TBL] [Abstract][Full Text] [Related]
9. Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancer.
Williams SB; Kacker R; Winston D; Bahnson E; Steele GS; Richie JP
J Urol; 2011 Dec; 186(6):2245-8. PubMed ID: 22014805
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors.
Cost NG; Lubahn JD; Adibi M; Romman A; Wickiser JE; Raj GV; Sagalowsky AI; Margulis V
J Urol; 2014 May; 191(5 Suppl):1485-90. PubMed ID: 24679874
[TBL] [Abstract][Full Text] [Related]
11. MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis.
Albers P; Bierhoff E; Neu D; Fimmers R; Wernert N; Müller SC
Cancer; 1997 May; 79(9):1710-6. PubMed ID: 9128986
[TBL] [Abstract][Full Text] [Related]
12. Surgical aspects in the treatment of patients with testicular cancer.
Richie JP
Hematol Oncol Clin North Am; 1991 Dec; 5(6):1127-42. PubMed ID: 1663937
[TBL] [Abstract][Full Text] [Related]
13. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection.
Hermans BP; Sweeney CJ; Foster RS; Einhorn LE; Donohue JP
J Urol; 2000 Jun; 163(6):1721-4. PubMed ID: 10799168
[TBL] [Abstract][Full Text] [Related]
14. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
Yoon GH; Stein JP; Skinner DG
Expert Rev Anticancer Ther; 2005 Feb; 5(1):75-85. PubMed ID: 15757440
[TBL] [Abstract][Full Text] [Related]
15. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only.
Nicolai N; Miceli R; Artusi R; Piva L; Pizzocaro G; Salvioni R
J Urol; 2004 Jan; 171(1):172-6. PubMed ID: 14665870
[TBL] [Abstract][Full Text] [Related]
16. Concordance and prediction ability of original and reviewed vascular invasion and other prognostic parameters of clinical stage I nonseminomatous germ cell testicular tumors after retroperitoneal lymph node dissection.
Nicolai N; Colecchia M; Biasoni D; Catanzaro M; Stagni S; Torelli T; Necchi A; Piva L; Milani A; Salvioni R
J Urol; 2011 Oct; 186(4):1298-302. PubMed ID: 21849196
[TBL] [Abstract][Full Text] [Related]
17. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
Ondrus D; Ondrusova M; Hornak M; Matoska J
Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
[TBL] [Abstract][Full Text] [Related]
18. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
19. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
20. Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma.
Foster RS; Donohue JP
J Urol; 2000 Jun; 163(6):1788-92. PubMed ID: 10799183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
